Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study

BACKGROUND: Immune checkpoint inhibitors (ICIs) provided a paradigm shift for advanced non-small cell lung cancer (NSCLC) treatment and improved the clinical prognosis of such patients. Pembrolizumab is a humanized anti-programmed death cell protein 1 (PD-1) monoclonal antibody, approved for the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Tianxing, Ding, Yun, Chen, Long, Zhu, Lihuan, Lin, Jinlan, Zhang, Jiguang, Huang, Yangyun, Li, Wujin, Lin, Rongjia, Pan, Xiaojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867846/
https://www.ncbi.nlm.nih.gov/pubmed/33569208
http://dx.doi.org/10.21037/jtd-20-3413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867846/
https://www.ncbi.nlm.nih.gov/pubmed/33569208
http://dx.doi.org/10.21037/jtd-20-3413

Ejemplares similares